TECH Insider Trading

Insider Ownership Percentage: 3.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,157,753.28

Bio-Techne Insider Trading History Chart

This chart shows the insider buying and selling history at Bio-Techne by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Bio-Techne Share Price & Price History

Current Price: $49.87
Price Change: Price Decrease of -0.382 (-0.76%)
As of 04/29/2025 11:04 AM ET

This chart shows the closing price history over time for TECH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$50.25Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for Bio-Techne (NASDAQ:TECH)

98.95% of Bio-Techne stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TECH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$21Mbought$26MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2B-$1B$0$1B$2BTotal InflowsTotal Outflows
Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Read More on Bio-Techne

Today's Range

Now: $49.87
Low: $49.64
High: $50.39

50 Day Range

MA: $57.11
Low: $47.51
High: $65.56

52 Week Range

Now: $49.87
Low: $46.01
High: $85.57

Volume

52,641 shs

Average Volume

1,214,504 shs

Market Capitalization

$7.88 billion

P/E Ratio

50.33

Dividend Yield

0.64%

Beta

1.45

Who are the company insiders with the largest holdings of Bio-Techne?

Bio-Techne's top insider investors include:
  1. Charles R Kummeth (CEO)
  2. Roeland Nusse (Director)
  3. Kim Kelderman (CEO)
  4. Amy E Herr (Director)
Learn More about top insider investors at Bio-Techne.

Who are the major institutional investors of Bio-Techne?

Bio-Techne's top institutional investors include:
  1. Sumitomo Mitsui Trust Group Inc. — 1.28%
  2. Riverbridge Partners LLC — 0.39%
  3. Allspring Global Investments Holdings LLC — 0.39%
  4. Fort Washington Investment Advisors Inc. OH — 0.21%
  5. Conestoga Capital Advisors LLC — 0.21%
  6. Rhumbline Advisers — 0.19%
Learn More about top institutional investors of Bio-Techne stock.

Which institutional investors are selling Bio-Techne stock?

Within the previous quarter, TECH stock was sold by these institutional investors:
  1. Allspring Global Investments Holdings LLC
  2. First Citizens Bank & Trust Co.
  3. Envestnet Portfolio Solutions Inc.
  4. Riverbridge Partners LLC
  5. Bessemer Group Inc.
  6. Sumitomo Mitsui Trust Group Inc.
  7. Mn Services Vermogensbeheer B.V.
  8. New York State Teachers Retirement System
Within the last year, company insiders that have sold Bio-Techne company stock include:
  1. Charles R Kummeth (CEO)
  2. Roeland Nusse (Director)
Learn More investors selling Bio-Techne stock.

Which institutional investors are buying Bio-Techne stock?

During the previous quarter, TECH stock was purchased by institutional investors including:
  1. GAMMA Investing LLC
  2. Fort Washington Investment Advisors Inc. OH
  3. Harbor Capital Advisors Inc.
  4. SG Americas Securities LLC
  5. Rhumbline Advisers
  6. Teacher Retirement System of Texas
  7. Asset Management One Co. Ltd.
  8. Lecap Asset Management Ltd.